Cardio‐Kidney‐Metabolic Therapy Use Among Adults With Type 1 Diabetes and Chronic Kidney Disease
Main finding · Time to ≥30% UACR reductionResult — go to the resultHazard ratio 0.76 CI 0.61–0.95Authors' conclusion
CKM therapy was frequently used in patients with Type 1 diabetes and CKD, associated with UACR reduction and safe. These clinically relevant data warrant confirmation in randomised clinical trials.
Study context
- Population
- Adults with T1D and chronic kidney disease (CKD), Optum's Market Clarity database (US), January 1, 2016–December 31, 2023; baseline mean age 52 years, HbA1c 8.1%, eGFR 77 mL/min/1.73 m², median urinary albumin-to-creatinine ratio (UACR) 60.8 mg/gpropensity-score matched
- Participants
- 253 adults
- Exposure
- Cardio-kidney-metabolic (CKM) therapy vs no CKM therapy
- Outcome
- Time to 30% or more UACR reduction
Methodological detailspropensity-score matched, claims and electronic medical records database
- Propensity-score matched
- Claims and electronic medical records database
Main finding
Time to ≥30% UACR reduction
Hazard ratio
0.76
CI 0.61–0.95
P = 0.0158
CKM therapyvs Controls
HR 0.76 (CI 0.61–0.95); P = 0.0158
As reported in the abstract
Observational data: associations, not effects.
Further findings
CKM therapy use
- CKM therapy used by more than 10% of patients with T1D and CKD
Safety
- Rates of hypoglycaemia and DKA not increased with CKM therapy
Original publication
Cardio‐Kidney‐Metabolic Therapy Use Among Adults With Type 1 Diabetes and Chronic Kidney Disease. Diabetes Obes Metab. Published 12 March 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →